29. Dezember 2020 -
GNA Biosolutions Receives Emergency Use Authorization from German Health Authority BfArM for Rapid Molecular SARS-CoV-2 Batch Testing System
German molecular diagnostics startup GNA Biosolutions has received Emergency Use Authorization (Sonderzulassung) from the German Federal Institute for Drugs and Medical Devices (BfArM) for the GNA Octea SARS-CoV-2 Test System. The new technology developed by GNA Biosolutions enables decentralized COVID-19 rapid tests in approximately 40 minutes without sacrificing sensitivity.